Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Non-Current Debt: 2022-2024

  • Abivax's Non-Current Debt rose 72.80% to $73.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $73.8 million, marking a year-over-year increase of 72.80%. This contributed to the annual value of $73.8 million for FY2024, which is 72.80% up from last year.
  • According to the latest figures from Q4 2024, Abivax's Non-Current Debt is $73.8 million, which was up 72.80% from $42.7 million recorded in Q4 2023.
  • Over the past 5 years, Abivax's Non-Current Debt peaked at $73.8 million during Q4 2024, and registered a low of $16.6 million during Q4 2022.
  • For the 3-year period, Abivax's Non-Current Debt averaged around $44.4 million, with its median value being $42.7 million (2023).
  • Data for Abivax's Non-Current Debt shows a peak YoY surged of 157.77% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Abivax's Non-Current Debt stood at $16.6 million in 2022, then soared by 157.77% to $42.7 million in 2023, then skyrocketed by 72.80% to $73.8 million in 2024.
  • Its last three reported values are $73.8 million in Q4 2024, $42.7 million for Q4 2023, and $16.6 million during Q4 2022.